NCT00694863

Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy

Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether treatment with long-acting synthetic adrenocorticotropic hormone is in the treatment of patients with idiopathic membranous nephropathy and high for renal failure.

Conditions

• Idiopathic Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	tetracosactide hexacetaat	Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.

Timeline

• Start date: 2008-07-01
• Primary completion: 2010-12-01
• Completion: 2012-12-01
• First posted: 2008-06-11
• Last updated: 2013-01-07

Locations

1 site across 1 country: Netherlands